Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial.

• Tác giả: Xunming Ji, Chuanhui Li, Sijie Li, Qingfeng Ma, Yue Qiao, Jing Wang, Pingping Wang, Chuanjie Wu, Ting Yang, Wenbo Zhao
• Ngôn ngữ: eng
• Thông tin xuất bản: England : European stroke journal , 2025
• Bộ sưu tập: NCBI
• ID: 58156

Tóm tắt

 INTRODUCTION: The degree of culprit artery stenosis affects the risk of early neurological deterioration (END) after acute ischemic stroke (AIS). The TREND trial demonstrated the efficacy of tirofiban in preventing END in patients with AIS. We aimed to investigate whether the degree of intracranial artery stenosis affects the efficacy of tirofiban in preventing END in patients with AIS. PATIENTS AND METHODS: We conducted a post hoc analysis of the TREND trial, which enrolled patients within 24 h of onset and randomly allocated to receive intravenous tirofiban or oral aspirin. We stratified the stenosis degrees into three subgroups: no stenosis, mild-to-moderate stenosis (stenosis <
 70%), and severe stenosis or occlusion (stenosis ⩾70%). The primary endpoint is END RESULTS: A total of 296 patients were analyzed. In patients with severe stenosis or occlusion, tirofiban significantly reduced the incidence of END DISCUSSION AND CONCLUSION: Tirofiban may significantly reduce the incidence of END in patients with severe arterial stenosis or occlusion. Further studies are required to confirm the effects of intracranial artery stenosis on the benefits of intravenous tirofiban. TRIAL REGISTRATION: ClinicalTrials.gov
  identifier: NCT04491695.